Pfizer

HCP Segmentation Insights

Ulcerative Colitis — 191-Feature Deep Analytics
Pipeline Stable
Executive Summary
Real KPIs from 20,931 HCPs across 86-week longitudinal panel
Total HCPs
0
86-week longitudinal panel
Labeled Cohort
0
56.9% of total market
Unlabeled Pool
0
Pending classification
Feature Columns
0
7 feature blocks engineered
Deep Learning Recall
0
On minority class (SEG_C)
Data Source: All metrics are computed from hcp_analysis_clean.parquet (20,931 HCPs × 191 columns). KPIs reflect real aggregated prescribing, engagement, and market share data across the 86-week observation window.
Population Distribution
Labeled Target Breakdown
Key Metrics by Segment (Labeled Cohort)
Segment Deep-Dive
Behavioral profiling from actual 191-column feature engineering
Segment A — Traditional
Lowest prescribing volume (0.17 UC TRx/wk). Only 3.8% show Pfizer growth. Highest rep effort per Rx (0.94 details/TRx). Status-quo prescribers resistant to new therapies.
Population6,406 (53.8%)
UC TRx/week0.171
Pfizer Share of UC0.36%
Active Weeks46.1%
Details per Rx0.94
Low Priority — Baseline
Segment B — Relationship
Highest Pfizer growth signal (9.6% growing). Most efficient rep conversion (0.44 details/TRx). Broadest promo engagement (2.56 channels). The primary commercial target.
Population3,349 (28.2%)
UC TRx/week0.517
Pfizer Share of UC0.48%
Active Weeks73.3%
Details per Rx0.44
High Priority — Target
Segment C — Didactic
Highest UC volume (0.71 TRx/wk) and strongest biologic loyalty (11.3% IL-23 share). Most efficient rep relationship (0.38 details/TRx). Protocol-driven, evidence-based HCPs.
Population2,144 (18.0%)
UC TRx/week0.711
Pfizer Share of UC0.31%
Active Weeks76.8%
Details per Rx0.38
Upsell Target — Deep Learning Focus
UC TRx Volume by Segment
Medication Mix by Segment
HCP Longitudinal Journeys
Visualizing the 86-week sequential data fed into the tensors
JC
Dr. James Chen
San Francisco, CA — Relationship-Centric
Segment B
Avg Weekly TRx Volume
14.2
86-Week Interactions
High
SW
Dr. Sarah Williams
Chicago, IL — Didactic / Cautious
Segment C
Avg Weekly TRx Volume
6.8
86-Week Interactions
Moderate
ML
Dr. Maria Lopez
Houston, TX — Traditional Prescriber
Segment A
Avg Weekly TRx Volume
12.0
86-Week Interactions
Low
Brand1 Adoption & Trajectory
Adoption funnel, growth signals, and recency trends from real data
91.4%
Never Tried Brand1
5.0%
Currently Active
2.6%
Trialed Then Lapsed
Adoption Funnel by Segment (% of each segment)
Adoption Funnel by Segment (Absolute Count)
Growth Signals: Who Is Accelerating?
Pfizer TRx: 86-Week Average vs. Recent 8 Weeks
Competitive Intelligence
Pfizer vs Brand2 market dynamics across segments
3.90×
Brand2/Pfizer — SEG_A
4.43×
Brand2/Pfizer — SEG_B
4.29×
Brand2/Pfizer — SEG_C
Competitive Pressure: Brand2 outprescribes Pfizer by 3.9–4.4× across all segments. The gap is widest in SEG_B (4.43×), the very segment with the highest Pfizer growth trajectory — indicating an active battleground for share.
Pfizer vs Brand2: Market Share of UC (%) by Segment
Brand2/Pfizer Prescribing Ratio by Segment
UC TRx Volume vs Pfizer Market Share (Labeled HCPs)
Rep Engagement ROI
Measuring commercial efficiency: visits, channels, and prescribing impact
0.94
Details/Rx — SEG_A
0.44
Details/Rx — SEG_B
0.38
Details/Rx — SEG_C
2.1×
SEG_B is 2.1× more efficient than SEG_A
Engagement Metrics by Segment
Rep Visits vs Pfizer Prescribing (Scatter)
Unlabeled HCP Opportunity
Prioritizing 633 unclassified HCPs for commercial outreach
39
Tier 1 — Immediate
Score ≥ 0.60. Highest prescribing + growth signals.
14
Tier 2 — Validate
Score 0.35–0.60. Moderate opportunity, needs validation.
580
Tier 3 — Monitor
Score < 0.35. Low activity, monitor for emergence.
Coverage Gap: 347 of 633 unlabeled HCPs (54.8%) have zero rep visits. Among Tier 1 (high-opportunity) HCPs, many prescribe actively but have never been contacted by a sales representative.
Live Model Prediction: Segment Classification

Test the live Hugging Face model (SEG_A vs SEG_BC) with sample HCP data.

Opportunity Score Distribution (633 Unlabeled HCPs)
Click a red point to identify the HCP below ↓
```
Specialty & Demographics
HCP specialty distribution across segments
HCPs by Specialty and Segment (Stacked)
Specialty Composition (% within each specialty)